ClinicalTrials.gg
TerminatedNCT02521792Updated Oct 19, 2020Results posted

In-Home Evaluation of Episodic Administration of Palovarotene in Fibrodysplasia Ossificans Progressiva (FOP) Subjects

A Phase 2 interventional study of Palovarotene in Fibrodysplasia Ossificans Progressiva, sponsored by Clementia Pharmaceuticals Inc.. Terminated at 2 sites in United States. Open to participants aged 6 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-10-19.

Sponsored by Clementia Pharmaceuticals Inc. (part of Ipsen) · Phase 2, Interventional, and Treatment

Why this study was terminated
Subjects were enrolled into a different Phase 2 study (PVO-1A-202, NCT02279095).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
6 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Myositis Ossificans by Ipsen — 1 open to participants now, 1 under way, none of them phase 3. Myositis Ossificans · Ipsen.

Started
2015
the only one that year
Phase 2
4 of 10
none open now
Registered
4th of 10
by date

Among the 10 studies in Myositis Ossificans by Ipsen, this one is the only one that started in 2015, is one of 4 in phase 2, and was the 4th registered.

Myositis Ossificans

24 studies on the registry are indexed under Myositis Ossificans; 5 are open to participants now.

Browse Myositis Ossificans studies →

Open to participants now

1 of the 10 studies in Myositis Ossificans by Ipsen is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 4 Myositis Ossificans studies recruiting now, 2 set no upper age limit and 1 stops at 75 or younger; 4 take children under 18; none take healthy volunteers.

This study: 6 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Myositis Ossificans by Ipsen, or all of them as a file.
02

Study summary

Fibrodysplasia Ossificans Progressiva (FOP) is a rare, severely disabling disease characterized by painful, recurrent episodes of soft tissue swelling (flare-ups) that result in abnormal bone formation (heterotopic ossification or HO) in muscles, tendons, and ligaments. Flare-ups begin early in life and may occur spontaneously or after soft tissue trauma, vaccinations, or influenza infections. Recurrent flare-ups progressively restrict movement by locking joints leading to cumulative loss of function and disability. Mouse models of FOP have demonstrated the ability of retinoic acid receptor gamma (RARγ) agonists such as palovarotene to prevent HO following injury. This 36-month study will evaluate the long-term safety and efficacy of episodic treatment with palovarotene for flare-ups in FOP subjects who successfully complete two flare-up treatment periods (6 weeks duration) and two follow-up periods (6 weeks duration) in Study PVO-1A-202.

Read the detailed description

The primary objective of this Phase 2, open-label, multicenter, single-arm, extension study is to investigate the safety and efficacy of episodic treatment with palovarotene in FOP subjects with flare-ups.

Secondary objectives are:

The effect of episodic treatment of flare-ups with palovarotene on range of motion (ROM) as assessed by the subject global assessment of movement.

  • The effect of episodic treatment of flare-ups with palovarotene on ROM as assessed by the Cumulative Analogue Joint Involvement Scale for FOP (CAJIS) for subjects with video-conferencing capability.
  • The effect of episodic treatment of flare-ups with palovarotene on the total burden of heterotopic ossification (HO) as assessed by low-dose whole body computerized tomography (WBCT), excluding the head; and whole body dual energy x-ray absorptiometry (DEXA).
  • The effect of episodic treatment of flare-ups with palovarotene on physical function using age-appropriate forms of the FOP-Physical Function Questionnaire (FOP-PFQ).
  • The effect of episodic treatment of flare-ups with palovarotene on physical and mental health using age appropriate forms of the Patient Reported Outcomes Measurement Information System (PROMIS) Global Health Scale.
  • The effects of episodic treatment of flare-ups with palovarotene on pain and swelling associated with the flare-up using numeric rating scales (NRS) or the Faces Pain Scale-Revised (FPS-R) in subjects under 8 years of age.
  • The use of assistive devices and adaptations for daily living by FOP subjects.

The follow-up portion of the study will consist of a Screening visit that will correspond to the last day (Study Day 84) of Study PVO-1A-202 and bi-annual assessments at Months 6, 12, 18, 24, 30, and 36.

Subjects experiencing a new, distinct flare-up during the 36-month follow-up will be evaluated and if eligible, receive palovarotene at the weight-adjusted equivalent of 10 mg for 14 days followed by 5 mg for at least 28 days. Any subject who received a lower dosing regimen due to tolerability issues during Study PVO-1A-202 will receive that tolerated dose.

For each flare-up there will be two periods:

  1. A Screening period to occur within 7 days of the start of a new, distinct flare-up. The first dose of palovarotene will be taken within 10 days of the flare-up onset to allow for shipment of study medication to the subject's home.
  2. A treatment period of at least 6 weeks duration. Subjects experiencing a new, distinct flare-up will be evaluated
03

Conditions studied

  • Fibrodysplasia Ossificans Progressiva

Keywords

  • Open-label study
  • Clinical trial Phase 2
  • Efficacy and safety
  • Heterotopic ossification
  • Fibrodysplasia Ossificans Progressiva
  • Flare-up
  • Palovarotene
  • Retinoic acid receptor agonist
  • Retinoic acid receptor gamma agonist
  • Clementia
  • Myositis Ossificans Progressiva
  • Munchmeyer's Disease
  • FOP
04

Who can participate

Ages eligible
6 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For study enrollment

  • Completed Study PVO-1A-202 having been treated with palovarotene (ie, 6 weeks on-treatment and 6-weeks follow-up) for two flare-ups.
  • Written, signed, and dated or age-appropriate subject/parent assent (this must be performed according to local regulations).

For treatment with palovarotene for subsequent flare-ups

  • Symptomatic onset of a new, distinct flare-up within 10 days of the first dose of study drug. Symptoms must be reported by the subject, be consistent with their previous flare-ups, and include a subject-reported onset date. The flare-up must be confirmed by the physician at screening via telephone contact and/or video-conferencing.
  • Females of (FOCBP) must have a negative blood (or urine) pregnancy test (with sensitivity of at least 50 mIU/mL) prior to administration of palovarotene. Male and FOCBP subjects must agree to remain abstinent during treatment and for 1 month after treatment or, if sexually active, to use two highly effective methods of during and for 1 month after treatment. Additionally, sexually active FOCBP subjects must already be using two highly effective methods of birth control 1 month before treatment is to start. Specific risk of the use of retinoids during pregnancy, and the agreement to remain abstinent or use two highly effective methods of birth control will be clearly defined in the informed consent, and the subject or legally authorized representatives (eg, parents, caregivers, or legal guardians) must specifically sign this section.
  • Subjects must be accessible for treatment with palovarotene and follow-up.

Exclusion criteria

Exclusion Criteria:

For study enrollment

  • Any reason that, in the opinion of the Investigator, would lead to the inability of the subject and/or family to comply with the protocol.

For treatment with palovarotene for subsequent flare-ups:

  • Weight \<20 kg.
  • The flare-up is at a completely ankylosed joint.
  • Intercurrent non-healed fracture at any location.
  • If currently using vitamin A or beta carotene, multivitamins containing vitamin A or beta carotene, or herbal preparations, fish oil, and unable or unwilling to discontinue use of these products during palovarotene treatment.
  • Exposure to synthetic oral retinoids in the past 30 days prior to screening (signature of the or age-appropriate subject assent).
  • Concurrent treatment with tetracycline or any tetracycline derivatives due to the potential increased risk of pseudotumor cerebri
  • History of allergy or to retinoids or lactose.
  • Female subjects who are breastfeeding.
  • Subjects with uncontrolled cardiovascular, hepatic, pulmonary, gastrointestinal, endocrine, metabolic, ophthalmologic, immunologic, psychiatric, abnormal laboratory findings, or other significant disease.
  • Simultaneous participation in another interventional clinical research study within the past 4 weeks (except for Study PVO-1A-202).
  • Subjects experiencing suicidal ideation (type 4 or 5) or any suicidal behavior within the past month prior to Screening as defined by the Columbia Suicide Severity Rating Scale.
  • Any reason that, in the opinion of the Investigator, would lead to the inability of the subject and/or family to comply with the protocol.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Palovarotene

    The protocol is open only to the subjects who completed Clementia Study PVO-1A-202. Eligible subjects will receive a weight-based equivalent dose of palovarotene 10 mg once daily for 14 days, followed by 5 mg once daily for 28 days. Should treatment be extended beyond 6 weeks, a weight-based equivalent dose of 5 mg will be administered in 2-week increments.

    Drug: Palovarotene

Interventions

  • Palovarotene will be taken orally once daily at approximately the same time each day. Powder filled hard gelatin capsules may be opened and the contents added onto specific food.

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Treatment-emergent Adverse Events (TEAEs)

    The primary endpoint was the safety of palovarotene as assessed by the incidence of TEAEs (including those known to be associated with retinoids) and serious adverse event (SAEs) monitored throughout the treatment period. TEAEs were adverse events reported during treatment with palovarotene or within 6 weeks after the end of treatment. Day 1 was the first day that study drug was administered for a flare-up. The number of subjects experiencing at least one TEAE or treatment-emergent SAE are presented.

    Time frame: Day 1 until 6 weeks after the end of treatment (an expected average treatment of 6 weeks). Assessed until data cut-off for study termination (maximum of 35 days).

Secondary outcomes

  1. Subject Global Assessment of Movement as Determined by a Subject Completed Questionnaire, or Proxy Completed Questionnaire in Subjects Under 8 Years of Age

    Time frame: Every 6 weeks while on study drug, at the end of treatment (should treatment be extended beyond 6 weeks), and 6 weeks after the end of treatment.

  2. Change From Baseline in Cumulative Analogue Joint Involvement Scale for FOP as Assessed by the Investigator Using Remote Video-conferencing

    Time frame: Baseline (flare-up screening), every 6 weeks while on study drug, at the end of treatment (should treatment be extended beyond 6 weeks), and 6 weeks after the end of treatment.

  3. Change From Baseline in Extent of Heterotopic Ossification (HO) by Whole Body Low-dose Computerized Tomography (CT) Scan, Excluding the Head

    Time frame: Baseline (final visit for Study PVO-1A-202/Part A) and at end of study (36 months).

  4. Change From Baseline in Extent of HO by Whole Body Dual Energy X-ray Absorptiometry (DEXA) Scan

    Time frame: Baseline (screening/enrollment visit) and at end of study (36 months).

  5. Change From Baseline in Pain and Swelling at the Flare-up Site Using Numeric Rating Scales, or Faces Pain Scale-Revised in Subjects Under 8 Years of Age

    Time frame: Baseline (flare-up screening), every 2 weeks while on study drug, at the end of treatment (should treatment be extended beyond 6 weeks), and 6 weeks after the end of treatment.

  6. Change From Baseline in Physical Function Using Age-appropriate Forms of the FOP-Physical Function Questionnaire

    Time frame: Baseline (flare-up screening), every 6 weeks while on study drug, at the end of treatment (should treatment be extended beyond 6 weeks), and 6 weeks after the end of treatment, and 6-month intervals for duration of study.

  7. Change From Baseline in Physical and Mental Health Using Age-appropriate Forms of the Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health Scale

    Time frame: Baseline (flare-up screening), every 6 weeks while on study drug, at the end of treatment (should treatment be extended beyond 6 weeks), 6 weeks after the end of treatment, and 6-month intervals for duration of study.

  8. Duration of Active, Symptomatic Flare-up as Assessed by the Subject and the Investigator

    Time frame: Baseline (flare-up screening), after 6 weeks on study drug, and every 2 weeks after Week 6 until flare-up resolution.

  9. Change From Baseline in the Use of Assistive Devices and Adaptations for Daily Living by FOP Subjects

    Time frame: Baseline (flare-up screening), 6 weeks after the end of treatment, and 6-month intervals for duration of study.

07

Results

Posted Oct 19, 2020
Limitations and caveats
The study was stopped prematurely and due to the small number of evaluable subjects, there was insufficient data to conduct any efficacy analyses. Consequently, no summary statistics are available for any of the secondary outcome measures.

Participant flow

Fibrodysplasia Ossificans Progressiva (FOP) subjects treated with palovarotene for 2 flare-ups in Study PVO-1A-202/Part A were enrolled. During enrolment, the dosage regimen for Study PVO-1A-202/Part B was optimized. Study PVO-1A-203 was terminated and participating subjects enrolled into Study PVO-1A-202/Part B to receive the modified regimen.

Participant flow — Overall Study
MilestonePalovarotene
Started6
Received treatment4
Completed0
Not completed6
Withdrew: Study terminated6

Outcome measures

PrimaryNumber of Subjects With Treatment-emergent Adverse Events (TEAEs)

The primary endpoint was the safety of palovarotene as assessed by the incidence of TEAEs (including those known to be associated with retinoids) and serious adverse event (SAEs) monitored throughout the treatment period. TEAEs were adverse events reported during treatment with palovarotene or within 6 weeks after the end of treatment. Day 1 was the first day that study drug was administered for a flare-up. The number of subjects experiencing at least one TEAE or treatment-emergent SAE are presented.

Time frame:
Day 1 until 6 weeks after the end of treatment (an expected average treatment of 6 weeks). Assessed until data cut-off for study termination (maximum of 35 days).
Reported as:
Count of participants · Participants
Number of Subjects With Treatment-emergent Adverse Events (TEAEs)
ParticipantsPalovarotene
TEAE4
Treatment-emergent SAE1
SecondarySubject Global Assessment of Movement as Determined by a Subject Completed Questionnaire, or Proxy Completed Questionnaire in Subjects Under 8 Years of Age
Time frame:
Every 6 weeks while on study drug, at the end of treatment (should treatment be extended beyond 6 weeks), and 6 weeks after the end of treatment.

No measurements were reported for this outcome.

SecondaryChange From Baseline in Cumulative Analogue Joint Involvement Scale for FOP as Assessed by the Investigator Using Remote Video-conferencing
Time frame:
Baseline (flare-up screening), every 6 weeks while on study drug, at the end of treatment (should treatment be extended beyond 6 weeks), and 6 weeks after the end of treatment.

No measurements were reported for this outcome.

SecondaryChange From Baseline in Extent of Heterotopic Ossification (HO) by Whole Body Low-dose Computerized Tomography (CT) Scan, Excluding the Head
Time frame:
Baseline (final visit for Study PVO-1A-202/Part A) and at end of study (36 months).

No measurements were reported for this outcome.

SecondaryChange From Baseline in Extent of HO by Whole Body Dual Energy X-ray Absorptiometry (DEXA) Scan
Time frame:
Baseline (screening/enrollment visit) and at end of study (36 months).

No measurements were reported for this outcome.

SecondaryChange From Baseline in Pain and Swelling at the Flare-up Site Using Numeric Rating Scales, or Faces Pain Scale-Revised in Subjects Under 8 Years of Age
Time frame:
Baseline (flare-up screening), every 2 weeks while on study drug, at the end of treatment (should treatment be extended beyond 6 weeks), and 6 weeks after the end of treatment.

No measurements were reported for this outcome.

SecondaryChange From Baseline in Physical Function Using Age-appropriate Forms of the FOP-Physical Function Questionnaire
Time frame:
Baseline (flare-up screening), every 6 weeks while on study drug, at the end of treatment (should treatment be extended beyond 6 weeks), and 6 weeks after the end of treatment, and 6-month intervals for duration of study.

No measurements were reported for this outcome.

SecondaryChange From Baseline in Physical and Mental Health Using Age-appropriate Forms of the Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health Scale
Time frame:
Baseline (flare-up screening), every 6 weeks while on study drug, at the end of treatment (should treatment be extended beyond 6 weeks), 6 weeks after the end of treatment, and 6-month intervals for duration of study.

No measurements were reported for this outcome.

SecondaryDuration of Active, Symptomatic Flare-up as Assessed by the Subject and the Investigator
Time frame:
Baseline (flare-up screening), after 6 weeks on study drug, and every 2 weeks after Week 6 until flare-up resolution.

No measurements were reported for this outcome.

SecondaryChange From Baseline in the Use of Assistive Devices and Adaptations for Daily Living by FOP Subjects
Time frame:
Baseline (flare-up screening), 6 weeks after the end of treatment, and 6-month intervals for duration of study.

No measurements were reported for this outcome.

Adverse events

Collected over TEAEs were to be collected from Day 1 until 6 weeks after the end of treatment (an expected average treatment of 6 weeks). Assessed until data cut-off for study termination (maximum of 35 days).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Palovarotene0/4 (0%)1/4 (25%)4/4 (100%)
Most frequent serious events
Most frequent serious events
EventPalovarotene
MyoclonusNervous system disorders1/4
MyalgiaMusculoskeletal and connective tissue disorders1/4
Most frequent other events
Most frequent other events
EventPalovarotene
Dry skinSkin and subcutaneous tissue disorders2/4
Lip dryGastrointestinal disorders2/4
Dry eyeEye disorders1/4
EczemaSkin and subcutaneous tissue disorders1/4
TinnitusEar and labyrinth disorders1/4
PneumoniaInfections and infestations1/4

Baseline characteristics

All enrolled subjects were included in the baseline analysis.

Age, Categorical
Age, Categorical(Participants)Palovarotene
<=18 years0
Between 18 and 65 years6
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)Palovarotene
Female1
Male5
Region of Enrollment
Region of Enrollment(participants)Palovarotene
United States6
08

Study locations

2 sites
  • University of California San Francisco, Division of Endocrinology and Metabolism
    San Francisco, California 94143, United States
  • University of Pennsylvania, Center for Research in FOP & Related Disorders
    Philadelphia, Pennsylvania 19104, United States
09

References and documents

Publications

  • Shimono K, Tung WE, Macolino C, Chi AH, Didizian JH, Mundy C, Chandraratna RA, Mishina Y, Enomoto-Iwamoto M, Pacifici M, Iwamoto M. Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-gamma agonists. Nat Med. 2011 Apr;17(4):454-60. doi: 10.1038/nm.2334. Epub 2011 Apr 3. Erratum In: Nat Med. 2012 Oct;18(10):1592. PubMed 21460849 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2015 to primary completion in Aug 2016, 7 months.

Results were first posted in Oct 2020, 4 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2015
First posted
Aug 13, 2015
StartActual
Dec 7, 2015
Primary completionActual
Aug 4, 2016
CompletionActual
Aug 4, 2016
Results first posted
Oct 19, 2020
Last update
Oct 19, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 19, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02521792
Responsible party
Sponsor
First posted
Aug 13, 2015
Start date
Dec 7, 2015
Primary completion
Aug 4, 2016
Completion
Aug 4, 2016
Results posted
Oct 19, 2020
Last update
Oct 19, 2020

Study contacts

Ipsen Medical Director
study director · Ipsen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Palovarotene

Start the discussion